SG10201808738WA - Fusokines involving cytokines with strongly reduced receptor binding affinities - Google Patents

Fusokines involving cytokines with strongly reduced receptor binding affinities

Info

Publication number
SG10201808738WA
SG10201808738WA SG10201808738WA SG10201808738WA SG10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA
Authority
SG
Singapore
Prior art keywords
fusokines
strongly reduced
receptor binding
binding affinities
cytokines
Prior art date
Application number
SG10201808738WA
Other languages
English (en)
Inventor
Jan Tavernier
Jennyfer Bultinck
Sarah Gerlo
Gilles Uzé
Franciane Paul
Yann Bordat
Original Assignee
Vib Vzw
Univ Gent
Centre Nat Rech Scient
Univ Montpellier
Centre Hospitalier Regional Univ De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Gent, Centre Nat Rech Scient, Univ Montpellier, Centre Hospitalier Regional Univ De Montpellier filed Critical Vib Vzw
Publication of SG10201808738WA publication Critical patent/SG10201808738WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10201808738WA 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities SG10201808738WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306034 2013-07-18

Publications (1)

Publication Number Publication Date
SG10201808738WA true SG10201808738WA (en) 2018-11-29

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808738WA SG10201808738WA (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities
SG11201600163VA SG11201600163VA (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201600163VA SG11201600163VA (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Country Status (14)

Country Link
US (3) US10640542B2 (enExample)
EP (2) EP3022305B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN105705641B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2657060T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG10201808738WA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3411065B1 (en) 2016-02-05 2021-03-31 Orionis Biosciences BV Clec9a binding agents
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN109689087B (zh) 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3580230A1 (en) * 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
SG11202001063QA (en) 2017-08-09 2020-03-30 Orionis Biosciences Inc Clec9a binding agents and use thereof
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
WO2019152979A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP7773371B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド Ｃｌｅｃ９ａベースキメラタンパク質複合体
CN113767115B (zh) 2019-03-28 2025-05-02 奥里尼斯生物科学股份有限公司 治疗性干扰素α1蛋白
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL308018B2 (en) 2021-04-30 2025-04-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for altered MHC expression
WO2024112814A1 (en) * 2022-11-21 2024-05-30 Wisconsin Alumni Research Foundation SYNTHETIC IL6-IL1β FUSION CYTOKINE FOR PROMOTING T CELL CYTOTOXIC FUNCTION, T CELL PROLIFERATION, AND TUMORICIDAL ACTIVITY

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632372B2 (en) 1989-08-22 1992-12-24 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
EP2052081A1 (en) * 2006-08-02 2009-04-29 McGill University Fusion proteins and methods for modulation of immune response
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
CN103880965B (zh) 2007-09-21 2018-02-16 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
CN105031618A (zh) * 2009-11-02 2015-11-11 加利福尼亚大学董事会 用于细胞因子递送的穹窿体复合物
US9132146B2 (en) * 2009-12-23 2015-09-15 Gradalis, Inc. Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine
WO2011132189A2 (en) * 2010-04-22 2011-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd High affinity leptins and leptin antagonists
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
KR102050119B1 (ko) * 2012-01-20 2019-11-28 브이아이비 브이지더블유 표적화된 돌연변이 알파-나선형 다발 사이토카인
LT2822575T (lt) 2012-03-03 2020-06-25 Immungene, Inc. Sukonstruotos antikūno-mutantinio interferono sulietos molekulės
UA125637C2 (uk) * 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b

Also Published As

Publication number Publication date
EP3022305B1 (en) 2017-11-01
BR112016001036A2 (pt) 2017-10-24
IL243451A0 (en) 2016-03-31
US11358997B2 (en) 2022-06-14
KR20160108291A (ko) 2016-09-19
AU2014292371B2 (en) 2018-03-29
JP2020002155A (ja) 2020-01-09
CN105705641A (zh) 2016-06-22
BR112016001036B1 (pt) 2023-02-23
CA2917937A1 (en) 2015-01-22
SG11201600163VA (en) 2016-02-26
WO2015007536A2 (en) 2015-01-22
US20230054612A1 (en) 2023-02-23
US20190010199A1 (en) 2019-01-10
DK3299466T3 (da) 2019-11-18
WO2015007536A3 (en) 2015-03-19
JP6853317B2 (ja) 2021-03-31
MX2016000611A (es) 2016-09-29
AU2018203868B2 (en) 2019-12-05
KR102322510B1 (ko) 2021-11-08
CN110835376A (zh) 2020-02-25
CN110835376B (zh) 2023-08-04
JP2016525516A (ja) 2016-08-25
CN105705641B (zh) 2021-07-13
AU2018203868A1 (en) 2018-06-21
EP3299466B1 (en) 2019-09-11
US10640542B2 (en) 2020-05-05
MX375441B (es) 2025-03-06
ES2757501T3 (es) 2020-04-29
US12410222B2 (en) 2025-09-09
JP6580037B2 (ja) 2019-09-25
EP3022305A2 (en) 2016-05-25
AU2014292371A1 (en) 2016-02-04
HK1252831A1 (en) 2019-06-06
CA2917937C (en) 2022-11-01
EP3299466A1 (en) 2018-03-28
US20180155404A1 (en) 2018-06-07
ES2657060T3 (es) 2018-03-01
IL243451B (en) 2019-10-31

Similar Documents

Publication Publication Date Title
SG10201808738WA (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
HUE052406T2 (hu) Antitestek optimalizációja, amelyek limfocitaaktivációs gén-3-hoz (LAG-3) kötnek és azok felhasználása
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
PH12016500753B1 (en) Antibodies specific to fcrn
CL2016000219A1 (es) Proteinas de fusión terapéutica.
PL3004167T3 (pl) Białka wiążące antygen receptora onkostatyny m
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
SI3200822T1 (sl) Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171)
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EP2978437A4 (en) BULBING FUSION PROTEINS
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
LT3038633T (lt) Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
PH12016500826A1 (en) Anti-ccl17 antibodies
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MX2017007747A (es) Anticuerpos para il-17c.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
PT3681911T (pt) Proteínas de ligação ao recetor humano da trombina, par4
EP3297663A4 (en) Antibodies that bind to axl proteins
EA201790482A1 (ru) Модифицированные полипептиды vip3
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
GB201522314D0 (en) Latency associated protein construct for providing latency to TNFR2-immunoglobulin fusion proteins